Quick Answer
Citius Pharmaceuticals, Inc. reported Cash and Equivalents of $4.25 million for fiscal year 2025.
Citius Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $4.25M | +30.8% |
| 2024 | $3.25M | -87.7% |
| 2023 | $26.48M | -36.5% |
| 2022 | $41.71M | -40.5% |
| 2021 | $70.07M | +405.6% |
| 2020 | $13.86M | +75.6% |
| 2019 | $7.89M | -14.0% |
| 2018 | $9.18M | +186.6% |
| 2017 | $3.20M | +988.5% |
| 2016 | $294.4K | -81.9% |
| 2016 | $1.63M | +140.5% |
| 2015 | $676.1K | -56.4% |
| 2014 | $1.55M | +2753.6% |
| 2013 | $54.4K | — |
| 2013 | $0.00 | -100.0% |
| 2012 | $41.7K | +30756.3% |
| 2012 | $135.00 | -36.3% |
| 2011 | $212.00 | -91.5% |
| 2010 | $2.5K | — |
| 2010 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $7.72M | +601.9% | +81.6% |
| September 30, 2025 | $4.25M | +30.8% | -30.2% |
| June 30, 2025 | $6.09M | -66.0% | +22956.1% |
| March 31, 2025 | $26.4K | -99.8% | -97.6% |
| December 31, 2024 | $1.10M | -94.6% | -66.2% |
| September 30, 2024 | $3.25M | -87.7% | -81.8% |
| June 30, 2024 | $17.91M | -46.2% | +42.6% |
| March 31, 2024 | $12.56M | -56.8% | -38.3% |
- Citius Pharmaceuticals, Inc. showed an increase of +30.8% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from Citius Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: